Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 6, 2014, Pages 543-553

  Dai, Wangde ^a,b   Shi, Jianru ^a,b   Gupta, Ramesh C ^c   Sabbah, Hani N ^c   Hale, Sharon L ^a   Kloner, Robert A ^a,b  

^a Heart Institute of Good Samaritan Hospital   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Bendavia; Left ventricular remodeling; Mitochondria; Myocardial infarction

Indexed keywords

BENDAVIA; CYTOCHROME C; CYTOCHROME C OXIDASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TETRAPEPTIDE; UNCLASSIFIED DRUG; WATER; ARGINYL-2,'6'-DIMETHYLTYROSYL-LYSYL-PHENYLALANINAMIDE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE REMODELING; HEART LEFT VENTRICLE VOLUME; HEART MITOCHONDRION; HEART VENTRICLE REMODELING; NONHUMAN; RAT; SCAR; THERAPY EFFECT; WATER TREATMENT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; METABOLISM; MITOCHONDRION; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; CYTOCHROMES C; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE EXPRESSION REGULATION; MITOCHONDRIA; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84918570887     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000155     Document Type: Article

References (31)

1. Kloner RA, Leor J, Birnbaum Y. Remodeling, hibernation, and stunning. In: Poole-Wilson PA, Colucci WS, Massie BM, eds. Heart Failure. New York, NY: Churchill Livingstone Inc; 1997:109-125.
2. Mookadam F, Moustafa SE. Prevention of late postmyocardial infarction left ventricular remodeling: An update. Curr Heart Fail Rep. 2009;6:245-253.
3. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: A review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13-21.
4. Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012;59:969-978.
5. Kloner RA, Hale SL, Dai W, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide. J Am Heart Assoc. 2012;1:e001644.
6. Dai W, Kloner RA. Experimental cell transplantation therapy in rat myocardial infarction model including nude rat preparation. Methods Mol Biol. 2010;660:99-109.
7. Hale SL, Kloner RA. Left ventricular topographic alterations in the completely healed rat infarct caused by early and late coronary artery reperfusion. Am Heart J. 1988;116:1508-1513.
8. Kobayashi H, Gil-Guzman E, Mahran AM, et al. Quality control of reactive oxygen species measurement by luminol-dependent chemiluminescence assay. J Androl. 2001;22:568-574.
9. Long J, Ma J, Luo C, et al. Comparison of two methods for assaying complex I activity in mitochondria isolated from rat liver, brain and heart. Life Sci. 2009;85:276-280.
10. O'Toole JF, Patel HV, Naples CJ, et al. Decreased cytochrome c mediates an age-related decline of oxidative phosphorylation in rat kidney mitochondria. Biochem J. 2010;427:105-112.
11. Gupta RC, Mishra S, Yang XP, et al. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem. 2005;269:49-57.
12. Mishra S, Gupta RC, Tiwari N, et al. Molecular mechanisms of reduced sarcoplasmic reticulum Ca2+-uptake in human failing left ventricular myocardium. J Heart Lung Transplant. 2002;21:366-373.
13. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res. 2009;81:519-527.
14. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
15. Dai DF, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011;58:73-82.
16. Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22:1041-1052.
17. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250-1261.
18. Wu D, Soong Y, Zhao GM, et al. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am J Physiol Heart Circ Physiol. 2002;283:H783-H791.
19. Song W, Shin J, Lee J, et al. A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. Coron Artery Dis. 2005;16:407-410.
20. Cho J, Won K, Wu D, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18:215-220.
21. Brown DA, Hale SL, Baines CP, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia. J Cardiovasc Pharmacol Ther. 2014;19:121-132.
22. Reffelmann T, Könemann S, Kloner RA. Promise of blood- And bone marrow-derived stem cell transplantation for functional cardiac repair: Putting it in perspective with existing therapy. J Am Coll Cardiol. 2009; 53:305-308.
23. Jackson BM, Gorman JH, Moainie SL, et al. Extension of border zone myocardium in postinfarction dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:1160-1167.
24. Hu Q, Wang X, Lee J, et al. Profound bioenergetic abnormalities in periinfarct myocardial regions. Am J Physiol Heart Circ Physiol. 2006;291: H648-H657.
25. Ekhterae D, Hinmon R, Matsuzaki K, et al. Infarction induced myocardial apoptosis and ARC activation. J Surg Res. 2011;166:59-67.
26. Qian L, Van Laake LW, Huang Y, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med. 2011;208:549-560.
27. Razavi BM, Hosseinzadeh H, Movassaghi AR, et al. Protective effect of crocin on diazinon induced cardiotoxicity in rats in subchronic exposure. Chem Biol Interact. 2013;203:547-555.
28. Chen L, Gong Q, Stice JP, et al. Mitochondrial OPA1, apoptosis, and heart failure. Cardiovasc Res. 2009;84:91-99.
29. Marunouchi T, Abe Y, Murata M, et al. Changes in small heat shock proteins HSPB1, HSPB5 and HSPB8 in mitochondria of the failing heart following myocardial infarction in rats. Biol Pharm Bull. 2013;36:529- 539.
30. Nojiri H, Shimizu T, Funakoshi M, et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem. 2006;281: 33789-33801.
31. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171: 2029-2050.